Litigation

Recent Posts

3rd Circuit Says Design Defect Claims For Generic Fosamax Are Preempted
Posted on 1 May 2014 by Tom Moylan

PHILADELPHIA — (Mealey’s) Strict liability design defect claims involving generic versions of the osteoporosis drug Fosamax are preempted by federal law despite plaintiffs’ attempts to narrow U.S. Supreme Court case law, a panel of the... Read More

Tags: Third Circuit , preemption , In Re: Fosamax [Alendronate Sodium] Products Liability Litigation [No. II] , Mylan Pharmaceuticals Inc. , Sun Pharmaceutical Industries Inc. , Apotex Corp. , Litigation , osteoporosis drug , multidistrict litigation , Merck Sharp & Dohme Corp. , Fosamax , U.S. Supreme Court , MDL , torts , Watson Pharmaceuticals Inc. , Teva Pharmaceuticals USA , Barr Pharmaceuticals Inc.